Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
* Zydus plans to launch the drug under three brand names - SEMAGLYN, MASHEMA, ALTERME. * Unlike existing treatments that ?require multiplesingle-use pens, ?Zydus' single adjustable pen will let patientsselect different doses, lowering costs, ?it says. * Zydus holds exclusive rights to its reusable pen withprefilled cartridges. * Patent protection for ?semaglutide expires ?in India late ?inMarch 2026, triggering a ?rush among Indian drugmakers to preparelower-cost versions. * Semaglutide is the active ingredient in Danish drugmakerNovo Nordisk's blockbuster diabetes drug Ozempic and weight-lossdrug Wegovy. * In January, Zydus received approval ?from India's regulatorto make ?and sell generic versions ?of the weight-loss ?drugs. * Larger peer Dr Reddy's ?Laboratories is likely to ?launchits generic ?semaglutide injection in the country in March underthe brand name Obeda, Reuters reported ?earlier on ?Wednesday,citing two people familiar with the ?matter. (Reporting by Nishit Navin in
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, AbataceptBusiness Wire
- Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "buy (b-)" rating to a "hold (c+)" rating.MarketBeat
- Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
- Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]Seeking Alpha
RDY
Earnings
- 1/22/26 - Beat
RDY
Sec Filings
- 2/24/26 - Form 6-K
- 2/18/26 - Form 6-K
- 2/17/26 - Form 6-K
- RDY's page on the SEC website